Azitra, Inc. announced the successful completion of Cohort 1 in its Phase 1/2 trial for ATR04-484, a potential treatment for skin rash caused by EGFR inhibitors used in cancer therapy. The safety review committee approved moving to Cohort 2, which will enroll about 24 patients for further testing. This live biotherapeutic aims to address a common, painful side effect that disrupts cancer treatment for many patients. The FDA has granted Fast Track status to ATR04-484, highlighting its potential to meet a significant medical need.
Azitra, Inc.'s ATR-04 Phase 1/2 clinical trial progress is noted with Pluang's Health sector market snapshot as of Oct 01, 2026 17:52 WIB: out of 100 priced Health-sector US stocks, 42 rose and 46 fell. Notable movers include FLNA (Cassava Sciences Inc) at USD 0.98 with a 1-day change of +10.96% and a typical hold time on Pluang of 37 days, CTXR (Citius Pharmaceuticals Inc) at USD 0.56 with a 1-day change of +5.08%, and INO (Inovio Pharmaceuticals Inc) at USD 1.25 with a 1-day change of +2.46%.
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
PNC Financial Services Group received mixed analyst ratings on October 1, 2026. Evercore ISI maintained an Outperform rating but lowered its price target to $265 from $285, citing strong net interest income growth but caution on expenses and asset qu...
Accenture reported fiscal Q4 2026 earnings that exceeded analyst expectations with EPS of $3.29, up 46% year-over-year, and revenue of $18.68 billion, a 6% increase. The company also saw a 4% rise in new bookings to $22.17 billion, reflecting strong ...
Analysts have downgraded PepsiCo and lowered its price targets due to weak stock performance and sales challenges in its Frito-Lay North America segment. Despite efforts to improve products, sales remain sluggish, raising concerns about PepsiCo's ope...
